Professor Li is an international recognised leader in cancer researcher, with expertise in cancer biology, cancer biomarker discovery and validation, EV isolation and characterisation, EV subpopulation and single EV analysis, liquid biopsy, therapeutic resistance and developing personalised medicine. He has a career of 147 publications with 8345 Google citations (h-index: 57) in cancer research. He was awarded the NHMRC achievement award in prostate cancer biomarker translation as No 1 in Australia national level. Professor Li leads a highly productive research team including clinicians, research staff and students. Professor Li obtained his Bachelor of Medicine (B.M) degree in 1987 and Master of Science (MSc) degree in 1992 from the Henan Medical University, China. He obtained his PhD. degree in Faculty of Medicine, University of New South Wales (UNSW), Sydney, Australia, in 2000. After two years of Postdoctoral study at UNSW, he was awarded the US Department Defence Prostate Cancer Research New Investigate Award in 2003 and then became an independent investigator. and Advanced Materials. His Scopus h-index is 36 and Google i10 index is 80. Professor Li has attracted 7.2 million AU$ from different funding sources including NHMRC, ARC, US Department Defence, Cancer Institute NSW, and Prostate Cancer Foundation of Australia and Prostate and Breast Cancer Foundation (PBCF) as the principal investigator. He has supervised 16 PhD students as the principal supervisor or co-supervisor. Prof Li’s current research program is aimed at: a): To investigate novel biomarkers in extracellular vesicles (EVs) as liquid biopsy for cancer diagnosis, prognosis, therapeutic and developing personalized medicine. b): To investigate the mechanisms of cancer metastasis and chemo-/radio-resistance and role of tumour microenvironment, EV subpopulation, cancer stem cells and epithelial-mesenchymal transition in cancer progression. c): To use targeted cancer therapy, immunotherapy, or combination therapy to treat metastatic and therapeutic resistant prostate and breast cancers.